The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.
If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback